Sunday, June 12, 2022 9:30:19 AM
Topic: NICE Sticks it to Nissen!
On June 10, 2022, The National Institute for Health and Care Excellence (NICE, England) published the Final Draft Guidance which recommends icosapent ethyl for reducing the risk of cardiovascular events such as heart attacks and strokes in adults who have raised levels of triglycerides. https://www.nice.org.uk/search?q=icosapent
This comes after a long process of gaining Marketing Authorization Approval in the EU & UK, (921 days), and 880 days after the failure of the STRENGTH Trial, (1/14/2020). For the past two and a half years the PI of that RTC (Dr. Steve Nissen) has been on a “sour grapes” campaign to discredit the results of the REDUCE-IT trial. In that 2.5-year period the FDA, the EMA and now NICE have correctly determined that the clinical effect of the mineral oil placebo had little to do with the final outcomes.
Recent AMRN News
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
